{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:32Z","timestamp":1792569332554,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12032-021-01549-z","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T04:02:50Z","timestamp":1627099370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"umin000024656","registry":"10.18810\/umin-japan"}],"author":[{"given":"Akiko","family":"Serizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-7393","authenticated-orcid":false,"given":"Hidekazu","family":"Kuramochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaho","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"issue":"6","key":"1549_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"33","key":"1549_CR2","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4387\u201393.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"1549_CR3","first-page":"1","volume":"11","author":"K Ott","year":"2008","unstructured":"Ott K, Lordick F, Herrmann K, et al. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2008;11(1):1\u20139.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"7","key":"1549_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/jso.23301","volume":"107","author":"Y Iwasaki","year":"2013","unstructured":"Iwasaki Y, Sasako M, Yamamoto S, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107(7):741\u20135.","journal-title":"J Surg Oncol"},{"issue":"6","key":"1549_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653\u201360.","journal-title":"Br J Surg"},{"issue":"6","key":"1549_CR6","first-page":"921","volume":"67","author":"Y Kidani","year":"1976","unstructured":"Kidani Y, Inagaki K, Tsukagoshi S. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gan. 1976;67(6):921\u20132.","journal-title":"Gan"},{"issue":"1","key":"1549_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(1):141\u20138.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"1549_CR8","first-page":"1","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2017;20(1):1\u201319.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"2","key":"1549_CR9","first-page":"101","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2011;14(2):101\u201312.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"2","key":"1549_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"},{"issue":"5","key":"1549_CR11","first-page":"1044","volume":"22","author":"M Terashima","year":"2019","unstructured":"Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2019;22(5):1044\u201352.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1549_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01136-7","author":"Y Iwasaki","year":"2020","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2020. https:\/\/doi.org\/10.1007\/s10120-020-01136-7.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"9","key":"1549_CR13","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s00595-015-1276-2","volume":"46","author":"Y Honma","year":"2016","unstructured":"Honma Y, Yamada Y, Terazawa T, et al. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surg Today. 2016;46(9):1076\u201382.","journal-title":"Surg Today"},{"issue":"1","key":"1549_CR14","doi-asserted-by":"publisher","first-page":"e000130","DOI":"10.1136\/esmoopen-2016-000130","volume":"2","author":"H Satake","year":"2017","unstructured":"Satake H, Miki A, Kondo M, et al. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open. 2017;2(1):e000130.","journal-title":"ESMO Open"},{"issue":"3","key":"1549_CR15","first-page":"919","volume":"19","author":"H Bando","year":"2016","unstructured":"Bando H, Yamada Y, Tanabe S, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2016;19(3):919\u201326.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1549_CR16","unstructured":"Ministry of Health, Labour and Welfare. Vital statistics Japan. 2016\u20132017, National Cancer Center, Japan (2016\u20132017) (Ministry of Health, Labour and Welfare, National Cancer Registry) Available via DIALOG. https:\/\/ganjoho.jp\/reg_stat\/statistics\/dl\/index.html. Accessed 24 Jan 2021."},{"issue":"3","key":"1549_CR17","first-page":"514","volume":"17","author":"Y Kurokawa","year":"2014","unstructured":"Kurokawa Y, Shibata T, Sasako M, et al. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2014;17(3):514\u201321.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"6","key":"1549_CR18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1200\/JCO.2005.01.305","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(6):1237\u201344.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1549_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2017.11.020","volume":"90","author":"S Spoerl","year":"2018","unstructured":"Spoerl S, Novotny A, Al-Batran SE, et al. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. Eur J Cancer. 2018;90:26\u201333.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1549_CR20","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/annonc\/mdx236","volume":"28","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin\/S-1 and docetaxel\/cisplatin\/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(8):1876\u201381.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"1549_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1245\/s10434-013-3055-x","volume":"21","author":"T Yoshikawa","year":"2014","unstructured":"Yoshikawa T, Tanabe K, Nishikawa K, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol. 2014;21(1):213\u20139.","journal-title":"Ann Surg Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01549-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01549-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01549-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T02:47:44Z","timestamp":1629773264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01549-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01549-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-418964\/v1","asserted-by":"object"}]},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HK received a scholarship grant from Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"98"}}